cancer care – Talk Bio

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

2 weeks ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates

Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

1 month ago talkbio0Tagged Artificial Intelligence, cancer care, Healthcare technology, oncology ecosystem, orchestration, patient navigation, Series D, strategic investors, Thyme Care, unicorn startup, Value-Based Care

Thyme Care; cancer care; Series D funding; AI orchestration; oncology ecosystem; value-based care; patient navigation; strategic investors; unicorn startup; healthcare technology

A Decade of Progress: Immuno-oncology on the Cusp of a New Era

12 months ago talkbio0Tagged Antibodies, Bispecific, cancer care, Cancer Research, Cancer Therapeutic Procedure, checkpoint inhibitors, immuno-oncology, Immunotherapy

Immuno-oncology, checkpoint inhibitors, bispecific antibodies, cancer treatment, immunotherapy, cancer research, future of cancer care.